<span style="font-family:lato-light,lato,sans-serif;" class="wixui-rich-text__text"> Publications

May

Modeling predicts direct-acting antiviral therapy for 5-weeks may cure recent or chronic hepatitis C infection among people with undetectable viral RNA by day 7

Goyal A, et al.

Scientific Reports picture_JPG_edited.png

May

Early Hepatitis B and Delta virus kinetics in patients undergoing liver transplantation

Battistella S, et al.

May

Modeling Highlights the Challenge of Achieving and Maintaining HCV Micro-Elimination Among People Who Inject Drugs

Tatara E, et al.

Screen Shot 2025-02-11 at 10.45_edited.png

May

Modeling in vitro cell-to-cell spread of hepatitis C viral infection using an agent-based approach

Shi Z, et al.

May

Modeling hepatitis D virus kinetics during bulevirtide monotherapy: challenges and solutions

Mhlanga A., et al.

May

Rat hepatitis E virus infection has multiphasic viral replication kinetics in vivo

Shi Z, et al.

Screen Shot 2024-09-23 at 2_edited_edited_edited_edited.png

July

Mathematical Modeling of HDV RNA, HBsAg, and ALT Kinetics in Patients with Compensated Cirrhosis: Insights from 96 Weeks of Bulevirtide Monotherapy

Mhlanga A., et al.

July

Mathematical Modeling of HDV RNA, HBV DNA, and HBsAg Dynamics during Lonafarnib-Based Therapy: Insights from the LOWR HDV-1 Study

July

Reply to Akiyama and Berk: Response-Guided HCV Therapy and the Imperative to Treat in Carceral Settings

Page K., et al.

2025

Screen Shot 2024-09-23 at 2.30_edited.jpg

January 2025

HBV serum RNA kinetics during nucleic acid polymers based therapy predict functional cure

Hershkovich, L., et al.

January 2025

Modeling of randomized hepatitis C vaccine trials: bridging the gap between controlled human infection models and real-word testing

Mackesy-Amiti, M., et al.

February 2025

Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy

Mhlanga A., et al.

April 2025

Modelling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytes

Shekhtman L., et al.

2022_Oren_PNG_edited_edited_edited_edite

April 2025

Functional cure for hepatitis B virus: challenges and achievements

Shechter O., et al.

May 2025

Challenges in coverage of future hepatitis C vaccines: Review and potential solutions

Ghandi K., et al.

May 2025

In-host modeling challenges using population approach methods

Mhlanga A., et al.

Screen Shot 2024-10-10 at 3.07.33 AM.png

July 2025

Hepatitis D Virus Infection: Pathophysiology, Epidemiology and Treatment. Report From the Third Delta Cure Meeting 2024

Degasperi, E., et al.

July 2025

Modeling of hepatitis B virus infection spread in primary human hepatocytes

Shi Z, et al.

July 2025

Modeling highlights the challenge of maintaining HCV micro-elimination among people who inject drugs

Tatara E, et al.

August 2025

The bioinformatics of the finding that the hepatitis delta virus RNA editing mechanism by a conformational switch exists in genotype 7 in addition to genotype 3

Zakh et al.

2024

December 2024

Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies

Shi Z, et al.

September 2024

Commentary on: Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D

Dahari, H., Cotler, SJ.

August 2024

Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice

Duehren, S., et al.

July 2024

Spatial inequities in access to medications for treatment of opioid use disorder highlight scarcity of methadone providers under counterfactual scenarios

Tatara, E., et al.

April 2024

Mathematical Models of Early Hepatitis B Virus Dynamics in Humanized Mice

Ciupe, S., et al.

Healthcare AI in M_edited_edited_edited_

March 2024

Reducing Sample Size While Improving Equity in Vaccine Clinical Trials: A Machine Learning-Based Recruitment Methodology with Application to Improving Trials of Hepatitis C Virus Vaccines in People Who Inject Drugs

Chiu, R., et al.

February 2024

Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies

Gopalakrishna, H., et al.

February 2024

Modelling HDV kinetics under entry-inhibitor Bulevirtide suggests the existence of two HDV-infected cell populations

Shekhtman, L., et al.

2023

October 2023

Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments

Shekhtman, L., et al.

July 2023

Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics

Hailegiorgis, A., et al.

July 2023

Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications

Sausen D., et al.

Screen Shot 2023-05-23 at 6_41_08 PM_edi

June 2023

Hepatitis delta virus RNA decline post inoculation in human NTCP transgenic mice is biphasic

Maya S., et al.

June 2023

Treatment of Chronic Hepatitis D with Peginterferon Lambda - The Phase 2 LIMT-1 Clinical Trial

Etzion O., et al.

April 2023

Rapid monophasic hepatitis B surface antigen decline during nucleic-acid polymers-based therapy predicts functional cure

Hershkovich, L., et al.

January 2023

Modeling-Based Response-Guided Hepatitis C Treatment during Pregnancy and Postpartum

Kushner, T., et al.

2022

December 2022

Hepatitis B and Hepatitis D Viruses:
A Comprehensive Update with an Immunological Focus

Sausen D., et al.

November 2022

Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring
Pathologies and Current Treatments

Shechter O., et al.

October 2022

Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients

Mhlanga A., et al.

June 2022

Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics

Reinharz V., et al.

March 2022

Modeling-based response-guided DAA therapy for chronic hepatitis C to identify individuals for shortening treatment duration

Goyal A., et al.

Screen-Shot-2016-05-10-at-12.06_edited.png

March 2022

Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago

Tatara E., et al.

January 2022

Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation

Shekhtman L., et al.

January 2022

Machine learning for mathematical models of HCV kinetics during antiviral therapy

Churkin A., et al.

January 2022

A meta-analysis of 20 years of data on people who inject drugs in metropolitan Chicago to inform computational modeling

Boodram B., et al.

2021

December 2021

A Mathematical Model for early HBV and -HDV Kinetics during Anti-HDV Treatment

Zakh R., et al.

November 2021

Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance

Shekhtman L., et al.

September 2021

Ginkgolic acid inhibits Coronavirus strain 229E infection of human epithelial lung cells

Bhutta M. S., et al

September 2021

Stress-Induced Epstein-Barr Virus Reactivation

Sausen D. G., et al

September 2021

Letter to the Editor: Examining HBV RNA kinetics during NA treatment - are NA multifunctional antiviral agents?

Dahari H., et al

August 2021

A Mathematical Analysis of HDV Genotypes: From Molecules to Cells

Zakh R., et al.

July 2021

HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection Dynamics

Durso-Cain, K., et al.

April 2021

Understanding hepatitis B virus dynamics and the antiviral effect of interferon-a treatment in humanized chimeric mice

Reinharz V., et al.

January 2021

Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed

Dahari H., et al.

January 2021

Understanding the antiviral effects of RNAi-based therapy on chronic hepatitis B infection

Kadelka S., et al.

2020

October

Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study

Etzion O., et al.

August

Efficient Methods for Parameter Estimation of Ordinary and Partial Differential Equation Models of Viral Hepatitis Kinetics

Churkin A., et al.

July

HCVMultiscaleFit: A Simulator for Parameter Estimation in Multiscale Models of Hepatitis C Virus Dynamics

Churkin A., et al.

June

Modeling based response guided therapy in subjects with recent hepatitis C infection

Gorstein E., et al.

May

Evaluation of short-course direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A single-centre, open-label study

Feld J.J., et al.

April

Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg

Shekhtman L, et al.

April

Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration

Dasgupta S, et al.

April

Sustained Virological Response Following an 11 Day Course of Direct Acting Antiviral Therapy for Hepatitis C Infection

Yardeni D, et al.

January

Modeling Challenges of Ebola Virus -Host Dynamics during Infection and Treatment

Chertow D.S., et al.

2019

Screen-Shot-2016-05-10-at-12.06_edited.p

January

Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography

Shteyer E, et al.

March

A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C

Koh C, et al.

March

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection

Tsuge M, et al.

April

Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago

Echevarria D, et al.

May

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis

Gambato M, et al.

Screen Shot 2024-10-10 at 1.43.52 AM.png

June

Multi-objective model exploration of hepatitis C elimination in an agent-based model of people who inject drugs

Tatara E, et al.

July

A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics

Reinharz V, et al.

July

Plasma hepatitis E virus kinetics in solid organ transplant patients receiving ribavirin

Lhomme S, et al.

2018

August

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics

Ishida Y, et al.

July

Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users

Major M, et al.

June

Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics

Reinharz V, et al.

April

Accounting for Space--Quantification of Cell-to-Cell Transmission Kinetics Using Virus Dynamics Models

Kumberger P, et al.

February

How to eliminate HCV in people who inject drugs in the USA

Dahari H, et al.

February

High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Networks Members

Boodram B, et al.

2017

December

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients

Canini L et al.

October

A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics

Reinharz V, et al.

Screen Shot 2024-09-23 at 2_edited_edite

August

Modeling HCV cure after an ultra-short duration of therapy with direct acting agents

Goyal A, et al.

June

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection

Canini L, et al.

May

End of treatment RNA-positive/sustained viral response in an individual with acute HCV infection treated with direct-acting antivirals

Shtyer E, et al.

January

Prevalence of End of Treatment RNA-Positivity/Sustained Viral Response in HCV Patients Treated with Sofosbuvir Combination Therapies

Malespin M, et al.

2016

June

HCV Kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

Dahari H, et al.

July

Hepatitis C virus cure after direct acting antiviral-related drug-induced liver injury: Case report

Hasin Y, et al.

September

HCV dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

DebRoy S, et al.

September

Resurrection of response-guided therapy for sofosbuvir combination therapies

Dahari H, et al.

September

Cure prevents more than HCV transmission

Dahari H, et al

2015

October

Oral Prenylation Inhibition with Lonafarnib in Chronic Hepatitis D Infection: a randomized, double-blinded, placebo controlled phase 2a trial

Koh C, et al.

September

Agent-based model forecasts aging of the population of people who inject drugs in metropolitan Chicago and changing prevalence of hepatitis C infections

Gutfraind A, et al.

August

Mathematical modeling of hepatitis C prevalence reduction with antiviral treatment scale-up in persons who inject drugs in metropolitan Chicago

Echevarria D, et al.

July

Quantification of HCV cell-to-cell spread using a stochastic modeling approach

Graw F, et al.

June

Effect of interferon-alfa therapy on hepatitis D virus

Guedj J, et al.

February

Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics

Dahari H, et al.

January

Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy

Canini L, et al.

2014

January

Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling

Rong L, et al.

Screen Shot 2024-10-16 at 5.46.46 AM.png

February

Effect of Ribavirin on Viral Kinetics and Liver Gene Expression in Chronic Hepatitis C

Rotman Y, et al.

June

Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approach.

Dahari H, et al.

December

Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling

Guedj J, et al.

2013

March

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a new estimate of the hepatitis C virus half-life

Guedj J, Dahari H. et al.

March

Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo.

Rong L, et al.

April

Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection

Zhang J, et al.

April

Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling

Dahari H. et al.

July

The HCV NS5A inhibitor daclatasvir has dual mode of action and reveals a shorter HCV half-life estimate.

Guedj J, et al.

September

Silymarin for HCV infection.

Polyak SJ, et al.

2012

January

Understanding silibinin's modes of action against HCV using viral kinetic modeling

Guedj J, Dahari H, et al.

February

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

Guedj J, et al.

2011

January

Hepatocyte proliferation and hepatitis C virus (HCV) kinetics.

Dahari H, et al.

2010

March

Thiazole antibiotics against breast cancer.

Halasi M, et al.

May

Rapid emergence of hepatitis C virus protease inhibitor resistance.

Rong L, et al.

May

Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes.

Dahari H, et al.

Screen Shot 2024-10-21 at 7.52.21 AM.png

August

The rate of hepatitis C virus infection initiation in vitro is directly related to particle density

Sabahi A, et al.

August

A Perspective on Modeling Hepatitis C Virus Infection.

Guedj J, et al.

September

Quantitative evaluation of HCV vaccine success: a meta-analysis.

Dahari H, et al.

September

Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.

Neumann AU, et al.

2009

January

Modeling complex decay profiles of hepatitis B virus during antiviral therapy.

Dahari H, et al.

Screen Shot 2024-10-21 at 7.29_edited.png

January

Analysis of hepatitis C virus infection models with hepatocyte homeostasis.

Reluga T, et al.

Screen Shot 2024-10-21 at 7.14_edited.pn

January

A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.

Dahari H, et al.

March

Modeling HCV kinetics: The relationship between the infected cell loss rate and the final slope of viral decay.

Dahari H, et al.

April

Hepatitis B virus clearance rate estimates.

Dahari H, et al.

April

Modeling subgenomic HCV RNA kinetics during interferon-a treatment.

Dahari H, et al.

Screen Shot 2024-10-21 at 6.52.32 AM.png

August

Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection.

Burg D, et al.

Screenshot 2025-08-04 at 3.26_edited.jpg

Mathematical modeling of HCV infection and treatment. HCV infection.

Dahari H, et al.

2008

Hepatitis C viral kinetics in special populations

Dahari H, et al.

2007

January

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated Interferon and ribavirin.

Dahari H, et al

June

Hepatitis C virus RNA kinetics: Drug efficacy and the rate of HCV-infected cells loss.

Dahari H, Perelson AS, et al.

July

Triphasic decline of HCV RNA during antiviral therapy.

Dahari H, et al

July

Modeling HCV Dynamics: Liver regeneration and critical drug efficacy.

Dahari H, et al

October

Mathematical modeling of subgenomic hepatitis C viral replication in Huh-7 cells.

Dahari H, et al

December

Hepatitis C virus kinetics in chimeric mice during antiviral therapy.

Dahari H, Perelson AS, et al.

2006

October

The extrahepatic contribution to HCV plasma viremia.

Dahari H, et al.

2005

Mathematical Modeling of Primary Hepatitis C Infection: Non-cytolytic clearance and early blockage of virion production.

Dahari H, et al.

PUBMED

Second Hepatitis C Compartment Indicated by Viral Dynamics during Liver Transplantation.

Dahari H, et al.

PUBMED

2004

March

Antiviral Action of Ribavirin in Chronic Hepatitis C.

Pawlotsky JM, et al.

June

Hepatitis C Virus Kinetics and Host Responses Associated with Disease and Outcome of Infection.

Major ME, et al.

2002

July

Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.

Bouvier-Alias M, et al.

2000

The-Journal-of-Infectious-Disease-600x40

July

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.

Neumann AU, et al.

1998

October

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Neumann AU, et al.